Trial Profile

Randomized Study of DOC1021 Dendritic Cell Immunotherapy in Combination with Standard of Care for Newly Diagnosed Adult Glioblastoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dubodencel (Primary)
Indications Glioblastoma
Focus Therapeutic Use
Sponsors Diakonos Oncology

Most Recent Events

30 May 2025 According to a Diakonos Oncology media release, the company announced the closing of a 20 million USD private placement of Simple Agreements for Future Equity (SAFE) to accelerate the companys Phase 2 glioblastoma trial for dubodencel, also known as DOC1021.
24 Mar 2025 Status changed from not yet recruiting to recruiting.
03 Feb 2025 Status changed to not yet recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com